Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2019
Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate CancerChristof Bernemann, Verena Humberg, Barbara Thielen, et al.
BJU International|March 31, 2015
The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 yearsMartin Boegemann, Carsten Stephan, Henning Cammann, et al.
Oncology Letters|November 29, 2023
Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancerMahmoud Abbas, Barbara Heitplatz, Christof Bernemann, et al.
Cancers|July 9, 2022
Artificial Intelligence-Based Prognostic Model for Urologic Cancers: A SEER-Based StudyOkyaz Eminaga, Eugene Shkolyar, Bernhard Breil, et al.
Future Oncology (London, England)|March 16, 2021
Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registryArne Strauss, Marianne Schmid, Michael Rink, et al.
Oncotarget|September 7, 2019
A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy settingMartin Boegemann, Katrin Schlack, Lena Früchtenicht, et al.
Future Oncology (London, England)|October 6, 2020
Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registryMartin Boegemann, Katrin Schlack, Michael Rink, et al.
Theranostics|July 21, 2020
Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand TherapyRobert Seifert, Konstantin Seitzer, Ken Herrmann, et al.
Annals of Nuclear Medicine|December 2, 2021
Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imagingKatharina Kessel, Robert Seifert, Matthias Weckesser, et al.
BMC Cancer|March 16, 2016
Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancerPhillip Mikah, Laura-Maria Krabbe, Okyaz Eminaga, et al.
Pageof 6